Nabriva nabs market-ready antibioticIrish Nabriva Therapeutics plc has acquired San Diego-based antibiotics developer Zavante Therapeutics for 8.2 million shares plus US$97.5m in milestone payments. more ➔
TxCell snapped up by SangamoUS gene editing expert Sangamo Therapeutics is set to acquire French biotech TxCell in an all-cash buyout of €72m on a debt- and cash-free basis. more ➔
Sobi in €387m orphan drug deal with NovimmuneSwedish Orphan Biovitrum AB (Sobi) has signed a €387 deal with Swiss drug developer Novimmune for a late stage antibody targeting a rare haematology disorder. more ➔
Novartis pays €945m for eczema programmeEuropean biotechs Morphosys and Galapagos have handed over their joint atopical dermatitis programme MOR106 to Novartis for up to €945m. The Swiss pharma giant aims to strengthen its commitment to … more ➔
IMI to spur on antibiotics research amidst big pharma pullbackThe Innovative Medicines Initiative has launched a new Antimicrobial Resistance Accelerator Programme after Novartis announced its retreat from antibiotics research only days ago. more ➔
Roche granted breakthrough status for liver cancer comboRoche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giant’s mAb combination therapy for liver cancer. more ➔
Epigenetic biomarkers predict immunotherapy successUK biotech Oxford BioDynamics has presented data showing that the company’s blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. more ➔
Urovant launches US$150m IPOSwiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron. more ➔
Immunooncology: Genmab teams up with ImmaticsDanish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications. more ➔
Big Data: Tracking cancer risk genesUsing only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk. more ➔
